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Abstract: In this review, we described different factors that modulate pluripotency in stem cells,
in particular we aimed at following the steps of two large families of miRNAs: the miR-200 family
and the miR-302 family. We analyzed some factors tuning stem cells behavior as TGF-β, which plays
a pivotal role in pluripotency inhibition together with specific miRNAs, reactive oxygen species
(ROS), but also hypoxia, and physical stimuli, such as ad hoc conveyed electromagnetic fields.
TGF-β plays a crucial role in the suppression of pluripotency thus influencing the achievement
of a specific phenotype. ROS concentration can modulate TGF-β activation that in turns down
regulates miR-200 and miR-302. These two miRNAs are usually requested to maintain pluripotency,
while they are down-regulated during the acquirement of a specific cellular phenotype. Moreover,
also physical stimuli, such as extremely-low frequency electromagnetic fields or high-frequency
electromagnetic fields conveyed with a radioelectric asymmetric conveyer (REAC), and hypoxia
can deeply influence stem cell behavior by inducing the appearance of specific phenotypes, as well
as a direct reprogramming of somatic cells. Unraveling the molecular mechanisms underlying the
complex interplay between externally applied stimuli and epigenetic events could disclose novel
target molecules to commit stem cell fate.
Keywords: stem cells; miRNA; epigenetics; cell reprogramming
1. Introduction
Epigenetics is a physiological phenomenon of heritable changes in gene function that do not
involve changes in the DNA sequence [1]. These changes of cellular and physiological phenotypic traits
may result from external or environmental factors, or they may be part of a normal developmental
program. In the last years, researchers have focused on the intertwining of epigenetic changes
and stem cell dynamics. One of the most extraordinary mechanism that has been described to
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influence epigenetic processes is the involvement of non-coding RNA transcripts [1–5], in particular
microRNAs (miRNAs). Epigenetic regulation by miRNAs can influence some functional aspects and
the differentiation of stem cells towards different cell lineages. Several studies confirm the important
role of miRNAs involved in cell life during differentiation, growth, expansion, and apoptotic processes.
Moreover, miRNAs have arisen as critical molecular regulators for maintaining the functions of stem
cells by finely tuning the levels of different signaling proteins [4,5]. In stem cells, this requires a
massive and rapid transformation in the cellular phenotype, and prompt important changes in the
proteomic network. miRNAs are able to suppress the translation of many target mRNAs, thus inducing
fluctuations in gene expression [6]. Approximately, thousands of miRNAs have been identified so
far, making miRNAs one of the most abundant classes of gene regulatory molecules in animals [7].
Nevertheless, understanding the mechanisms accounting for their function is still a remarkable
challenge. In fact, owing to the important role and functions of miRNAs in regulating many cellular
decisions related to pathological processes, they could be evaluated as new therapeutic targets for
drug development in the treatment of many diseases. Understanding miRNA biogenesis, regulation,
and mechanism in controlling stem cell differentiation will enhance the likelihood for success in stem
cell-based therapeutic approaches, including tissue regeneration and engineering. Within this context,
an interesting pathway is the relationship between miRNAs and TGF-β signaling, which has been
extensively investigated. Studies by different authors suggest that TGF-β-related signals can either
inhibit or enhance miRNA maturation [8,9], being themselves regulated by these small molecules.
The aim of the present review is to present the role of specific miRNAs in regulating stem cell patterning,
by influencing their pluripotency and differentiation capability. A section will be dedicated to the
influence of specific physical stimuli, as electromagnetic fields, on stem cell epigenetic fate.
2. Stem Cells
Stem cells are undifferentiated cells that can differentiate into specialized cells or divide to
produce more stem cells. In mammals, there are two broad types of stem cells: embryonic stem cells,
which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in
various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the
body, replenishing impaired tissues, having the remarkable potential to develop into many different
cell types.
The key characteristics of stem cells are:
1. Asymmetric divisions with the formation of stem cells (self-regeneration or self-renewal) and
daughter cells with reduced differentiation potential, which transiently replicate and thus
differentiate after a specific number of divisions;
2. The persistence of the replicative capacity for the entire life of the individual;
3. The maintenance a source of stem cells due to a specific microenvironment (stem cell niche)
formed by other cells.
Self-regeneration is the ability to create an undifferentiated cell perfectly identical to the original
stem cell (SC). Their cellular power (plasticity or stemness) is indeed the ability to develop into highly
specialized cell types for specific biological functions. Depending upon the pluripotency, we can
distinguish different types of stem cells. Totipotency is the ability to give rise to all embryonic and
extraembryonic tissues, and is essentially restricted to the earliest stages of embryonic life, when the
embryo is formed by only four or eight cells. Pluripotency is the ability to differentiate in all embryonic
tissues, typical of the embryonic SC (ESCs) and of the induced pluripotent SC (IPSCs). Multipotency
the ability of one of the three germinative layers (endoderm, mesoderm, or ectoderm), or a specific
tissue, to differentiate into different cell types and is associated with adult SC. Finally, unipotency is
the ability to differentiate into a single cell type [10,11].
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3. Embryonic and Adult Stem Cells. Cellular Reprogramming and Generation of Pluripotent
Stem Cells
Human Embryonic stem Cells (hESCs) were described for the first time in 1998 after being
isolated from the internal cellular masses of human blastocysts which were donated for research
purposes [12]. These cells were characterized, in vivo, through the formation of teratomas and, in vitro,
through the expression analysis of specific enzymatic markers and assays, and through differentiation
studies [12]. Unlike animal models, it is not possible, for ethical reasons, to perform chimerism studies
and transmission to the germ line on hESCs. It is known that stem cells (both human and murine) have
the ability to replicate indefinitely in vitro, although there are differences both at the gene expression
level and at the growth medium conditions (e.g., the use of the Leukemia Inhibitory Factor—LIF—is
indispensable for murine stem cells, but it is not necessary for human ones) [13].
4. Induced Pluripotent Stem Cells (iPSCs)
In 2006, Yamanaka, Nobel Prize for Medicine or Physiology in 2012, and his Collaborators at the
University of Kyoto identified conditions that could “genetically reprogram” specialized adult cells to
assume a state similar to that of stem cells. These adult cells, called induced pluripotent stem cells
(iPSCs), have been reprogrammed by introducing important genes able to induce self-renewal and
essential differentiation capability, like in ESCs. The strategy used was the nuclear reprogramming,
a technique that experimentally induced a stable change in the nucleus of a mature cell, which can
be maintained during the following cellular divisions. These changes are most frequently associated
with the reacquisition of a pluripotent state, thereby providing the cells with a developmental
potential [14]. This approach uses mature “somatic” cells from the adult and introduces the genes
encoding critical transcription factors, which in turn regulate other key genes for the early steps
in embryonic development. Four transcription factors (Oct4, Sox2, Klf4, and c-Myc) were required
to reprogram mouse fibroblasts (cells found in the skin and other connective tissues) to acquire an
embryonic-like state [8]. These factors were known to be involved in the maintenance of pluripotency.
The newly-created iPSCs were found to be highly similar to ESCs and could be produced after several
weeks in culture [8,9]. In 2007, two different research groups reached a new milestone by deriving
iPSCs from human cells, using either the original four genes [10] or a different combination containing
Oct4, Sox2, NANOG and Lin28 [11,15]. Since then, Researchers have generated iPSCs from somatic
tissues of monkeys [14] and rats [16,17]. However, these cells can retain methylation patterns from
their original cells, a phenomenon called epigenetic memory, which has been shown to influence the
differentiation potential [18]. Several studies analyzed the operating system in iPSCs in the context
of reprogramming yield. Armstrong et al. [19] compared iPSCs with ESCs, showing that reactive
oxygen species (ROS) levels and mitochondrial mass are similar in these cells and significantly less
than in human dermal fibroblasts from which iPSCs were first generated. These cells are expected to
reproduce the behavior of ESCs in response to oxidative stress (OS). Armstrong et al. [20] also found
a reduced number of mitochondria in pluripotent stem cells, as compared to fibroblasts. The loss of
mitochondria appears to be a key step in the reprogramming process, being linked to a switch from
an oxidative to a glycolytic-dependent metabolism [21]. It has been shown that to support their high
proliferation rates, pluripotent stem cells are predominantly anabolic and tend to inactivate catabolic
pathways. Consequently, energy production is obtained through glycolysis rather than oxidative
phosphorylation, which is related to the decrease in the number of mitochondria [22,23]. A recent study
suggests that some miRNAs play a fundamental role in regulating differentiation and maintaining
pluripotency/multipotency in stem cells [24].
5. miRNAs
miRNAs are a type of non-coding RNA, 21–24 nucleotides in length, that function in the
post-transcriptional regulation of gene expression. They can be found as isolated transcript units or
clustered and co-transcribed as polycistronic primary transcripts [25]. Typically a miRNA interacts,
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through its specific sequence named Seed, with specific mRNAs through complementary base-pairing,
to influence the translation or stability of the target mRNA molecule. MiRNA life is subjected
to multipurpose regulation [26], beginning with the transcription of its own genes. The resulting
transcribed RNA sequence is folded into a hairpin structure and then processed in the nucleus
by Drosha (a class 2 ribonuclease enzyme III) in a new structure called pre-miRNA. Exportin-5
exports the hairpin pre-RNA from the nucleus to the cytoplasm. Subsequently, another endonuclease,
called Dicer, catalyzes pre-miRNA deployment into mature miRNA. Argonaut and helix proteins are
co-recruited to form the RNA-induced silencing complex (RISC) that allows the control of miRNA
with consequent translational repression, and destabilization cleavage for post-transcriptional protein
regulation. Most targeted miRNA sites are found in the 3′untranslated regions (3′UTR) of mRNA
transcripts [27]. However, other studies have shown that targeted miRNA sites may reside beyond
3’UTR in mRNA protein encoding sequences [28]. Some pre-miRNAs can be secreted from the cells
in the extracellular environment, becoming circulating miRNAs [29], to exert their role in other cells
within the tissue or in different tissues. MiRNAs regulate genes and define cell fate and behavior.
One of the main miRNA control and regulation mechanisms is represented by transforming growth
factor beta (TGF-β) signaling [8,9].
6. Stem Cells, TGF-β, and Epigenetics
TGF-β is a multifunctional cytokine belonging to the transforming growth factor superfamily
that includes four different isoforms (TGFB1, TGFB2, TGFB3, and TGFB4) and many other signaling
proteins produced by all white blood cell lineages [8,9]. Activated TGF-β recruits other factors to
form a serine/threonine kinase complex that binds to the TGF-β receptors, which comprises both
type 1 and type 2 receptor subunits. After binding TGF-β, the two receptor subunits undergo a
cross phosphorylation, then the activated receptor recruits the signaling cascade of small mother
against decapentaplegic (SMAD) proteins [30,31]. This leads to the activation of different downstream
targets and regulatory proteins, inducing the transcription of different target genes involved in
differentiation, chemotaxis, proliferation, and activation of many immune cells [32]. A defect in
the growth inhibitory response to TGF-β often correlates with the malignancy of many types of
cancers [33]. Among the TGF-β protein signaling, Activin/Nodal branch is essential for maintaining
pluripotency in hESCs [34–36]. Components of the hESC core transcriptional regulatory circuitry [37],
such as NANOG represent one of the target genes that are activated by Smad2/3 [38,39]. One of
the key events in acquiring stem cell properties of both breast cancer and normal mammary stem
cells is an epithelial-mesenchymal transition (EMT) induced by TGF-β. TGF-β family signaling
regulates stemness of normal and neoplastic stem cells by exerting different effects depending upon
the cell type, the microenvironment and physiological state of the cells [40,41]. Recent evidence
indicates an association between miRNAs and TGF-β signaling, providing a new insight into the
deepness of these interactions that are also the basis of pluripotency and cell differentiation [42,43].
The relationship between TGF-β and miRNA signaling has been extensively studied, unraveling both
an inhibitory or stimulatory role of the TGF-β pathway on the maturation of miRNAs [44]. Moreover,
Smad proteins have been shown to control the transcription of miRNA coding genes by binding their
gene promoter [45]. Smads control miRNAs synthesis by a Smad2-3 complex binding to Smad4 [44].
The Smad2-3-4 complex is moved to the nucleus where it binds to specific Smad binding elements
in the DNA, while the Smad3 is recruited from the Drosha/DGCR8 microprocessor complex and
promotes miRNA maturation [44,46,47]. The mechanisms that lie at the basis of the suggested activation
pathways have not been completely elucidated. Some of the known activation pathways are cell or
tissue-specific; others have been seen in response to many cytotoxic agents [48,49]. Some of the factors
that can trigger the TGF-β are: proteases, integrins, pH, and ROS (reactive oxygen species) [50,51].
The perturbation of one of these activating factors can lead to altered TGF-β levels which in turn bring
several outcomes such as: inflammation, autoimmune reactions, fibrosis, and cancer [52].
Molecules 2018, 23, 282 5 of 19
7. MicroRNAs and Cell Reprogramming
As reported above, Yamanaka and his Co-workers showed the feasibility to obtain pluripotent
progenitors from fibroblasts by forcing the expression of four genes: OCT3/4, Sox2, Klf4, and C-MYC,
the so called Yamanaka factors or OSKM [53]. This discovery is considered one of the most important
of the third millennium since it proved the chance of reversing life trajectories [54–56]. Interestingly,
some of those stem cell core regulators are able to activate the promoters of several miRNAs in ESCs,
including miR-290–295, miR-302-367, and miR-92clusters [57]. MiRNA analysis has defined that ESCs
and iPSCs have a distinct miRNA expression patterns, compared to differentiated somatic cells [58].
The miRNA-mediated reprogramming technique has been shown to be more efficient than the standard
OSKM over-expression method [59]. Furthermore, cell reprogramming mediated by miRNA may
provide a safer approach than traditional DNA reprogramming methods.
8. Stem Cell Function and miRNA Transcription
The mechanisms by which cells control the production and function of miRNAs have been recently
described [60]. MiRNAs transcription is regulated like protein coding genes, for example by DNA
methylation or through DNA promoter binding factors such as p53 or C-MYC [61]. As previously
stated, the factors Oct4, Sox2, and NANOG play a central role in acquiring and maintaining “stemness”:
these factors define the future of stem cells through several stages of self and mutual regulation.
Recent studies have revealed the transcription of many other actors in the Pluripotency Regulation
network, including LIN28, CMYC, Klf4, TCF3, or STAT3 [62]. Some of these nuclear stem cell regulators
are able to activate the promoters of different miRNAs in ESCs, including miR-290–295, miR-302–367
and miR-92 clusters [63]. MiRNAs are central players in the process of ESC self-renewal/differentiation.
The loss of mir-145 compromises differentiation and induces the expression of Oct4, Sox2 and Klf4 [45].
It also controls the differentiation of ESCs directly by targeting stem cell factors, thus silencing the
self-renewal program [45]. MiRNAs involved in maintaining the pluripotency of stem cells are
miR-200C and other miRNAs belonging to miR-203 family [46].
9. MiRNAs Orchestrating Stem Cell Pluripotency and Differentiation
Studies on mice, revealed that the miR-290–295 cluster and miR-296 were expressed in ESCs and
that their levels decrease during stem cell differentiation. This proved that the miR-290–295 cluster
had specific roles in maintaining pluripotency [64]. Interestingly, some nuclear stem cell regulators like
Oct4 are able to activate promoters of several miRNAs in ESCs, including miR-290–295, miR-302–367,
miR-371–373 and miR-92 clusters [63]. While miR-290–295 cluster is highly expressed in mESCs,
miR-302–367 and miR-371–373 clusters are mainly regulators in hESCs. Actually, the miR-290–295
cluster represents the mouse homologue of human miR-371–373 [65–69]. The human ESCs express
many members of the miR-302 family, as miR-302a, miR-302a*, miR-302b, miR-302b*, miR-302c,
miR-302c*, and miR-302d [70]. The overexpression of miR-302 in human cancer cell lines resulted
in their conversion into pluripotent cells that express key ESC markers such as Oct3/4, SSEA-3,
SSEA-4, Sox2, and NANOG [71]. These miRNAs (miR-302s, miR-369s and miR-200c) are highly
expressed in iPSCs and ESCs and are capable of reprogramming human somatic cells to acquire
the pluripotent state [72]. Some miRNAs are known to facilitate cellular reprogramming for the
generation of iPSCs, while other miRNAs can inhibit this process. This is achieved by reducing
directly or indirectly the expression of the pluripotent genes involved in cellular reprogramming.
In this regard, miR-34 (miR-34a, b, c) was found to suppress reprogramming of somatic cells by
deleting the expression of NANOG, Sox2, and N-Myc [73]. Other differentiation-related miRNAs,
as miR-296 and miR-470 were found to target coding regions of NANOG, SOX2 and OCT4 to promote
differentiation [74]. The transcriptional effects of miR-21 itself are regulated in ESCs by a transcriptional
repressor called the RE1-silencing transcription factor (REST). REST directly interacts with an upstream
cis-element of the miR-21-dependent transcription factors, thus promoting differentiation [75]. A recent
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study demonstrates that miR-21, which is induced following the commitment of mouse ESCs to
differentiation, has a potential binding sites in the 3′ UTRs of the mRNAs encoding for NANOG, SOX2,
and OCT4, thus modulating the corresponding protein levels [76]. MiRNAs regulation defines ESC
fate and behavior (Table 1).
Table 1. MiRNA regulation on stemness.
miRNA Influence on Pluripontecy Influence on Differentiation Inhibition of EMT /MET
miR-200 family yes no yes
miR-302 family yes no yes
10. The Two Big miRNA Families of Pluripotency: miR-200 and miR-302/367
10.1. MiRNA-200 Family
The miR-200 family comprises five members (miR-200a, miR-200b, miR-200c, miR-141,
and miR-429), located within two clusters on two different chromosomes: chromosomes 1 and 12 in
humans [77]. Members of the miR-200 family, directly activated by Oct4 and Sox2 able to bind to
their promoter regions, help fibroblasts to overcome the MET (Mesenchymal Epithelial transition)
barrier and facilitate iPSC generation. All members of the miR-200 family (miR-200a, miR-200b,
miR-200c, miR-141, and miR-429) are significantly more expressed in iPSCs and ESCs than in MEF
cells, suggesting that miR-200 family may correlate with pluripotency and that its activation may
promote the emergence of iPSCs. Members of the miR-200 family are specific and direct targets
for the key pluripotency-associated transcription factors Oct4/Sox2 in iPSC generation. However,
very little is known about the role and intrinsic regulation of the miR-200 family during iPSC generation.
Oct4 and Sox2 could bind the promoter region of miR-141/200c and miR-200a/b/429, respectively,
and activate the transcription of miR-200s. MiR-200 family members have been found to inhibit ESC
differentiation directly targeting Cadherin11 and Neuropilin1 [69]. Recently, it has been demonstrated
that the MET process is an important early event in iPSC generation [78], and that the activation of
EMT is associated with the maintenance of stem-cell properties [79]. Noteworthy, TGF-β induces
reversible DNA methylation of miR-200 promoters [80]. Moreover, miR-200b and miR-200c loci
can be reversibly de-methylated during prolonged signaling of TGF-β. Changes in the degree of
methylation of the miR-200 promoter are closely related to miR-200 expression, and repression.
The mechanism through which TGF-β controls the DNA methylation of miR-200 is not clear, but it
may involve the presence of active DNA Methyltransferases (DNAMTs). Even invasive mesenchymal
breast cancer cell lines show miR-200 methylated promoters, in contrast to epithelial cells where
miR-200 promoters were de-methylated. Similar observations have recently been yielded from
primary mesenchymal cells and invasive bladder tumors [81–83]. Furthermore, Gregorya et al. have
identified a central role for an autocrine TGF-β/ZEB/miR-200 signaling network in controlling the
transition between epithelial and mesenchymal states. Prolonged activation of this pathway leads
to epigenetic changes in miR-200 and may contribute to invasive breast cancer progression [84].
Considering these findings, a remarkable connection between EMT and breast cancer stem cells was
recently demonstrated, where TGF-β treatment was shown to initiate EMT-associated embryonic
differentiation programs of epithelial–mesenchymal, with EMT and MET representing a basic
mechanism for epithelial cell plasticity [79]. MET has been shown to be an important early event
in somatic cell reprogramming [76–85]. The miR-200 family and ZEB1 have been shown to be key
regulators of these processes [85,86]. A link among the TGF-β–related factors, the bone morphogenetic
proteins, and the miR-200 family have recently been described in somatic cell reprogramming [87]. It is
well known that the miR-200 family suppresses EMT. It has also been reported that the knockdown of
miR-200c inhibits NANOG and up regulates GATA4, thereby inhibiting self-renewal and promoting
hESC differentiation [88]. Transfection with a group of miRNAs including miR-200c, miR-302s,
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and miR-376s family successfully coaxed somatic cells into an iPSC fate [89]. As stated above,
TGF-β plays an important role in repressing the miR-200 [90].
10.2. The miR-302/367 Family
The miR-302/367 big family, comprises miR-367, miR-302d, miR-302a, miR-302c, miR-302b,
and miR-371/373. The miR-302 cluster is the most abundant miRNA family in hESCs, and can
promote somatic cell reprogramming, while miR-371–373, are less expressed [91]. The structure
of the gene coding for the human miR-302/367 cluster has been well characterized [92]. MiR-371,
miR-372, and miR-373 are gene clusters located in the region of the human chromosome 19q13.4.
They are the human equivalent of miR-290/295 in the mouse [93]. MiR-302/367 family is ubiquitously
distributed in vertebrates as a cluster spanning the La-related protein 7 (LARP7) intron, in the
4q25 region of human chromosome 4 [92]. The cluster was initially identified to be specifically
expressed in undifferentiated hESCs, and their malignant counterpart human embryonic carcinoma
cells (hECCs), and was found to play a role in pluripotency of stem cells and in cancer formation [92].
This cluster is highly expressed in, and therefore constitutes a signature miRNA for stem cells [93,94].
It is also highly expressed in iPSCs while progressively declining during differentiation [93].
The miR-290–295/miR-371–373 family members directly control the G1-S cell cycle transition and
inhibit apoptosis. This family also plays a significant role in regulating cell proliferation, differentiation
and reprogramming [95,96]. It was demonstrated that Oct3/4, NANOG, Rex1, and Sox2 act as
transcriptional activators of the miR-302/367 cluster [97,98]. This cluster is specifically expressed in
embryonic stem cells, iPSCs or tumor cells, to coordinate proliferation, differentiation, pluripotency,
maintenance, and reprogramming [99,100]. MiR-302 members repressed lysine-specific histone
demethylase 1 and 2 (AOF1 and AOF2) and methyl-CpG binding proteins (MECP1 and MECP2),
leading to destabilization of DNA methyltransferase 1, thus causing a genome-wide demethylation
promoting reprogramming and iPSC development [101]. Overexpression of the miR-302-367 cluster
significantly increased the conversion of reprogrammed iPSCs by repressing MBD2 (methyl-CpG
binding domain) expression, thereby inducing NANOG expression [102].
Another study found that the miR-302/TGF-β/Nodal/Smad-2/3 pathway was also involved
in EMT. In EMT, epithelial cells form monolayers and display elongated morphology and enhanced
motility [103]. MiR-302 members directly repressed the expression of the transforming growth factor
beta receptor 2 (TGFBR2), and the member C (RHOC) genes of the Ras family, thus allowing the EMT
process [92]. In addition, miR-302 members could negatively regulate the level of the TGF-β related
protein Lefty1 and Lefty2, thus becoming an upstream modulator of the TGF-β/Nodal signaling
pathway, finely tuning pluripotency and differentiation [104]. The main core promoter for this process
has been shown to include the embryonic stem cell factors NANOG, OCT3/4, SOX2, and REX1 [105].
This is an additional cue to consider the miR-302/367 cluster an important stem cell signature for
stem cells [92]. This cluster is also highly expressed in iPSCs where its expression decreases during
differentiation [105].
11. Epithelial–Mesenchymal Transition (EMT) in Stem Cells
TGF-β plays an important role during cell reprogramming in iPSC generation and pluripotency.
Fibroblasts undergoing MET adopt the epithelial state of pluripotent cells and conversely human
pluripotent stem cells resemble cells obtained from the epiblast [106]. The occurrence of EMT in
human pluripotent stem cells and embryoid bodies during cell commitment reflects the EMT observed
during gastrulation in human development [107]. By contrast, suppression of EMT by inhibiting
TGF-β signaling improves reprogramming efficiency [108]. The TGF-β signaling pathway promotes
EMT, and miR-302 promotes reprogramming partly decreasing the expression of TGF-β receptor 2,
and the related SMAD2 and/or SMAD3 phosphorylation and activation [109]. Furthermore, as stated
above, TGF-β plays an important role in repressing the miR-200. Members of the miR-200 family are
specific and direct targets for the key pluripotency-associated transcription factors Oct4/Sox2 in iPSC
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generation. These miRNAs act as regulators of EMT in many cell types. For example, snail promotes
EMT through the repression of miRNA 200 family members and induces mesoderm differentiation
during the epiblast stem cell stage, suggesting that miR-200 family members might suppress EMT and
the differentiation of ESCs at the epiblast stem cell stage [67]. These two major miRNAs families are
the basis of the pluripotency induction by interacting with the TGF-β, thus demonstrating that TGF-β
plays a crucial role in suppressing pluripotency by acting on the EMT [106]. Among the other TGF-β
may be triggered by ROS (reactive oxygen species) [50].
12. Hypoxia Exerts Opposite Effect on miR-200 and miR-302 Family
Hypoxia is broadly recognized as a mechanism that drives angiogenesis. Several possible
mechanisms have been proposed for down-regulation of miRNAs in a low oxygen environment [110].
MiR-200b down regulation is crucial in inducing angiogenesis via Ets-1 direct targeting. These findings
consolidate the notion that under hypoxic conditions miR-200b down-regulation is required to
relieve Ets-1 repression resulting in successful angiogenic outcomes. Furthermore, hypoxia-induced
angiogenesis, as well as Ets-1 up-regulation was rescued by delivery of the miR-200b mimic [110].
On the other hand, miR-302 expression was induced by hypoxia. Recent findings by other Authors
highlighted a central role of miR-302 overexpression during hypoxia/re oxygenation-mediated
cardiomyocyte apoptosis. In particular, this proapoptotic effect of miR-302 was mediated by
inhibiting the expression of the antiapoptotic molecule myeloid leukemia cell-differentiation protein-1
(Mcl-1) [111].
13. Physical Stimuli: Ad Hoc Conveyance of Electromagnetic Fields to Drive Stem Cell Fate
Previous studies revealed a role of reactive oxygen species (ROS) in transducing mechanically
or electrically-induced cardiovascular differentiation in mouse ESCs [112]. Moreover, fibroblast
direct reprogramming toward cardiogenic, neurogenic, and myogenic lineages occurred through
an upregulation of the NADPH oxidase isoforms Nox2 and Nox4 [113]. In the same paper, Maioli et al.
described an interesting biphasic effect on the expression of certain stemness related genes, elicited by
the Radio Electric Asymmetric Conveyer (REAC), an innovative device conveying radio electric fields
of 2.4 GHz. In particular, REAC-stimulation was able to induce an increase in the expression of
Oct4, Sox2, cMyc, NANOG, and Klf4 within 6–20 h, while downregulating the same genes following
prolonged times of exposure [113,114]. This study demonstrates the feasibility of using a physical
stimulus to afford the expression of stemness in human adult somatic cells up to the attainment
of three major target lineages (cardiogenic, neurogenic, and skeletal myogenic) (Figure 1). So far,
the acquirement of a pluripotent state in somatic cells, including fibroblast reprogramming to iPSCs or
direct reprogramming to cardiac or neuronal lineages without an iPSC intermediate, has only been
achieved by targeted genetic engineering through viral vector-mediated technologies or cumbersome
and expensive protein transduction methods or by combinatorial approaches encompassing both
viral-mediated gene delivery and chemical stimulation or gene-delivery and physical stimulation of
the target cells [114–116]. Electromagnetic fields (EL-EMFs) are also able to affect biological processes,
including stem cell development proliferation and differentiation [117].
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or electrically-induced cardiovascular differentiation in mouse ESCs [112]. Moreover, fibroblast 
direct reprogramming toward cardiogenic, neurogenic, and myogenic lineages occurred through an 
upregulation of the NADPH oxidase isoforms Nox2 and Nox4 [113]. In the same paper, Maioli et al. 
described an interesting biphasic effect on the expression of certain stemness related genes, elicited 
by the Radio Electric Asymmetric Conveyer (REAC), an innovative device conveying radio electric 
fields of 2.4 GHz. In particular, REAC-stimulation was able to induce an increase in the expression of 
Oct4, Sox2, cMyc, NANOG, and Klf4 within 6–20 h, while downregulating the same genes following 
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14. Electromagnetic Fields
Baek et al. showed that EMF exposure induces epigenetic changes that promote efficient
somatic cell reprogramming to pluripotency [118]. There is a general agreement on the effects of
EMF on biological systems. It was indicated that low-frequency electromagnetic fields affect cell
migration, cellular differentiation, apoptosis, and stress response [119,120]. EMF can also affect many
stages of embryonic development, which are of interest for morphology and migration of embryonic
cells [120,121]. Moreover, it was reported that EMFs of selected frequencies promote osteogenic and
neurogenic differentiation, a finding that has been clinically applied in repairing bone fractures and
promoting wound healing [122–124]. These studies indicate that EMFs can be involved in managing
the conversion of cell destiny. Stem cells respond to EMFs differently, depending on their state of
differentiation. It is possible that EMFs modulate the activity of transcription factors and the level of cell
cycle regulatory genes [125–127]. It is believed that one of the possible mechanisms of EMF biological
activity involves the generation of ROS within the cell. Excessive concentration of ROS, such as
superoxide anions (O2−) and hydrogen peroxide (H2O2), is considered to be cell destructive and results
in inhibition of gene expression. In contrast, small amounts of ROS function as intracellular second
messengers and activate signaling cascades involved in growth and differentiation of many cell types.
The high level of ROS modifies signaling pathways by phosphorylation mechanisms [128]. However,
the energy of a weak EMF is not sufficient to directly break a chemical bond in DNA [128]. Therefore,
it can be concluded that genotoxic effects are mediated by indirect mechanisms as microthermal
processes, generation of ROS, or disturbance of DNA repair processes [128]. Although ROS were
originally thought to be merely a harmful product of metabolism, accumulating evidence demonstrates
a role of ROS in cell fate signaling [128]. H2O2 is thought to be the main ROS species involved in
intracellular signaling, and in specific contexts can act directly as a second messenger, integrating
environmental cues and passing them to downstream signal transduction cascades [128,129]. This is
due mostly to the longer half-life of H2O2 and its ability to diffuse easier through membranes than
other types of ROS [129,130]. Slight variations in ROS content may have deep effects on stem cell
fate [130,131]. iPSCs and ESCs exhibit similar ROS levels and mitochondrial mass, but significantly
less than in human dermal fibroblasts from which iPSCs were generated. As stated before, the loss
of mitochondria appears to be a key step in the reprogramming process, and is linked to a switch
from an oxidative metabolism to a glycolytic-dependent state [132,133]. It has been recently shown
that maintaining low (physiological) O2 (2–5% O2) in cultures inhibits spontaneous differentiation
and supports pluripotency [132–134]. These studies provided evidence that molecular processes
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that mediate pluripotency and suppress differentiation are supported under 4%-O2 conditions and
that the cells retain a “memory” of their prior environment. Hypoxia induces the expression of
Sox2 and Oct4 genes that are related to stem cell function [135,136]. In particular, Sox2, together
with Sox4, was recently shown to play a pivotal role in the maintenance of stemness in ESCs.
Hypoxia has been demonstrated to induce EMT, which prompts invasion and metastasis from
cancer cells [135]. During EMT, epithelial cells undergo several biochemical alterations that allow the
acquisition of the mesenchymal phenotype enabling cancer cells to evade their “homeland” and to
colonize remote locations [135,136]. EMT-inducers, including TGF-β and hypoxia, trigger changes
in gene expression by complex signaling pathways [136]. The loss of polarity and gain of motile
characteristics of mesenchymal cells during embryonic development have suggested analogies with
metastatic cancer cells during malignant progression [135]. Notably, recent data on several cancer
types have demonstrated that EMT is involved in generating cells with properties of stem cells [136].
This implies that hypoxia-induced EMT may affect cancer stem cells (CSCs) or induce stem-like cells
from more differentiated progenitors determining an increase of CSC population responsible for early
systemic cancer dissemination and metastasis formation. Many studies have demonstrated a functional
connection between low oxygen level, ROS production, and EMT [134,137]. Indeed, in contrast to
cancer cells in which ROS levels are increased, CSCs generally maintain low ROS, exhibiting redox
patterns that are similar to the corresponding normal stem cells [137]. Diehn et al. reported that ROS
levels are lower in human and murine breast CSCs than in non-stem breast cancer cells [135].
15. ROS and miRNA
The miR-200 family has been extensively studied in the EMT of cancer cells [30].
In EMT, miR-200 family down-modulation enhances cancer aggressiveness and metastases,
whereas reintroduction of miR-200 family in some tumors inhibits their growth. ROS induces miR-200c
and other miR-200 family members; the following down-modulation of ZEB1 has a key role in
ROS-induced apoptosis and senescence [138]. Another study demonstrated that H2O2 and other
oxidant agents increase the expression of miR-200c and induce growth arrest, apoptosis, and senescence
in HUVEC cells by inhibition of ZEB1 expression [138]. Overall, these findings indicate a potential role
of miR-200 family in the regulation of ROS homeostasis [138]. The effect of miR-302s on cell survival
under oxidative stress has been shown to determine the effects of miR-302d on ROS, with a protective
role against oxidative stress [139]. Accordingly, miR-302d transfection significantly decreased the
generation of ROS, indicating that the protective action of miR-302 on oxidant-induced cell death may
be related to the inhibition of ROS generation [140].
As mentioned above, the interaction of miR-200 and miR-302 families with ROS is different.
Mir-200 family members increase after ROS stimulation, while miR-302 family act by lowering the
level of ROS. There are therefore opposite mechanisms that maintain cellular homeostasis and that
can be used to modulate pluripotency and differentiation in stem cells [138–141]. The mechanisms
that induce pluripotency and differentiation are complex, and not fully clarified. The interest of the
scientific world has increased since Yamanaka created iPSCs, paving a novel way to regenerative
medicine. To date, the limits of using iPSCs for regenerative purposes are caused by the use of viruses
to transport OCT4, SOX2, c-Myc, NANOG, or other pluripotency factors within the target. This can
cause teratoma and possibly cancer.
On the whole, our interest in writing this review was to understand how miRNAs work in stem
cells, cancer stem cells, or iPSCs. We also attempted in drawing the readers’ attention on transcription
factors, and physical stimuli that can be used to maintain pluripotency, or to induce differentiation.
16. Conclusions
In this review, we described epigenetic factors modulating pluripotency and stem cell behavior,
particularly the role of miRNAs. We considered two large miRNA families involved in plutipotency:
miR-200 family and miR-302 family. We analyzed some features of stem cells which encompass miRNA
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recruitment, biophysical stimuli, such as electromagnetic fields and REAC conveyed radioelectric
fields, and chemistry, like ROS and hypoxia. The REAC action bypassed a persistent reprogramming
toward an induced pluripotent stem cell-like state and involved the transcriptional induction of the
NADPH oxidase subunit Nox4 [112–115]. This finding demonstrates the feasibility of using a physical
stimulus to afford the expression of pluripotentiality in human adult somatic cells up to the attainment
of major complex lineages. It is believed that one possible mechanism involves the generation of
ROS within the cell. Excessive concentration of ROS is considered to be cell destructive and results
in inhibition of gene expression. In contrast, small amounts of ROS function as intracellular second
messengers and activate signaling cascades involved in growth and differentiation of many cell types.
This complicated regulatory mechanism is called “hormesis”. Hormesis can be considered an adaptive
function characterized by a dose-dependent biphasic response, which occurs as a result of exposure to a
very wide range of stimuli [142–144]. This intricate mechanism of activation and inhibition of miRNAs
and their targets leads to a fine stem cell homeostasis. MiR-200 and miR-302 are pluripotency activators
which trigger pluripotency genes (SOX2, OCT4, and NANOG). These two miRNAs families can be
modulated by physical and chemical factors. As showed in Figure 2, ROS induction leads to TGF-β
activation which acts blocking miR-200 and miR-302. Figure 2 shows the complex interplay occurring
between ROS, miR-200, and TGF-β and between hypoxia, miR302, and TGF-β. This factor, is directly
modulated by both of the above mentioned miRNAs, and acts itself by modulating cell differentiation
and reprogramming, in turn downregulating both miRNA 200 and miRNA 302. These two major
miRNA families are the basis of pluripotency induction by interacting with TGF-β, thus demonstrating
that TGF-β, with or without the involvement of ROS, plays a crucial role in suppressing pluripotency,
thus influencing stem cell behavior (Figure 3) [112]. Unravelling the hormetic factors, as for example
ROS, and their role in influencing stem cells pluripotency and differentiation capabilities could pave
the way to novel therapeutic approaches in regenerative medicine.
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